二次细胞减灭术治疗腹腔内复发卵巢上皮癌

为探讨对卵巢上皮癌和复发者进行二次细胞减灭术SCS)的治疗效果进行回顾性分析。研究对象为Texas大学肿瘤中心1985～1994年间收治的经历SCS的复发性卵巢上     

晚期卵巢上皮性癌清除腹膜后淋巴结价值的研究

目的 探讨晚期上皮癌行腹膜后淋巴结清除的价值。方法 ８５例晚期卵巢上皮癌患者根据清除腹膜后淋巴结与否分成Ａ、Ｂ两组，Ａ组４２例，Ｂ组４３例；再将两组患者根据肿瘤细胞减灭术（减灭术）后残瘤灶直径≥２ｃｍ和〈２ｃｍ分成两组进行比较。结果 两组５存活率分别为３８．１％和２７．９％（Ｐ〈０．０５）。Ａ组残瘤灶直径〈２ｃｍ与Ｂ组残瘤灶直径〈２ｃｍ存活率分别为５３．８％和３４．６％（Ｐ〈０．０５）；Ａ、Ｂ两组     

二次肿瘤细胞减灭术治疗复发性卵巢上皮性癌

由于持续性或复发性卵巢上皮性癌的生物学行为方式变幻末测 ,二次手术的作用难以确定。为此 ,作者进行了前瞻性的研究旨在测定二次肿瘤细胞减灭术对复发性卵巢上皮性癌患者生存率的影响。自 1993年 6月至 1999年 6月 ,作者对 14 9例持续性或复发性卵巢上皮性癌患者进行了二次肿瘤细胞减灭术。所有患者在初次手术后至少完成了 6个疗程的含顺铂的化疗方案的治疗。其中 FIGO 期 15例 , 期 16例 , 期 10 3例 , 期15例。初次治疗后无瘤生存期 (RFI) 7～ 12月者 6 3例(43.3% ) ,13～ 2 4月者 5 9例 (39.6 % ) ,>2 4月者 2 1例 (14 .1% )。术前 …     

正电子发射体层显像在诊断复发性卵巢恶性肿瘤中的价值

目的　探讨正电子发射体层显像 (PET)在诊断复发性卵巢恶性肿瘤中的价值。方法　选择行满意的肿瘤细胞减灭术 ,术后经 6～ 9个疗程的化学药物治疗 (化疗 ) ,临床完全缓解 6个月以上的 31例卵巢恶性肿瘤患者进行PET全身检查 35例次。在随访过程中同时进行PET和盆腹腔CT检查 2 2例次 ,通过二次探查术或再次肿瘤细胞减灭术并经病理学检查证实 ;13例次继续随访和结合多项检查进行评估 ,评价PET和CT在诊断复发性卵巢恶性肿瘤中的价值。结果　 35例次PET检查中 ,1例透明细胞癌为假阴性 ,1例内胚窦瘤化疗后PET检查为假阳性 ,PET检查的灵敏度为 96 3% ,特异性为 87 5 % ;CT的灵敏度为 70 4 % ,特异性为 75 0 %。PET和CT的灵敏度比较 ,差异有显著性(P <0 0 5 )。结论　应用PET诊断复发性卵巢恶性肿瘤的效果优于CT ,可提高复发性卵巢恶性肿瘤的早期诊断。     

再次细胞减灭术治疗卵巢上皮癌的探讨

再次细胞减灭术治疗卵巢上皮癌的探讨６３００４２重庆医科大学第一附属医院徐小蓉，卞度宏细胞减灭术是治疗晚期卵巢上皮癌的重要措施之一，但对于复发或术后残留病灶，再次进行细胞减灭术的价值如何，各家意见不一．本文就此进行了回顾性分析．资料１９８５年１月至１９...     

卵巢癌肠转移58例综合治疗分析

我院妇科自1983年3月至1992早12月以手术和多药联合化疗治疗卵巢癌肠转移58例。其中肠切除35例,肿瘤剥除23例。肠切除的35例中,有13例(37.1％)需造人工肛门。术后60.3％患者的残余肿瘤直径小於2cm。术后随访超过2年40例,超过5年17例。2年与5年存活率分别为45％及23.5％。初次手术的Ⅲ期、Ⅳ期癌及残余肿瘤小於2cm的预后远比复发癌及残余肿瘤大於2cm的好。本文认为预防严重并发症是提高治愈率的关键。     

理想的细胞减灭术仍是肝转移的Ⅳ期卵巢癌者的独立预后因素

为确定肝转移的Ⅳ期卵巢上皮性癌患者行理想肿瘤细胞减灭术的价值,回顾性分析37例经根治手术的Ⅳ期卵巢上皮性癌的临床资料。 37例患者的中位年龄为61(38～89)岁,所有患者均接受卵巢癌肿瘤细胞减灭术,其中1例术前行新辅助化疗。达到理想减瘤术,残余肿瘤<2cm者占43％(16/37例),<1cm占16.2％(6/37例)。31例(84％)行全子宫、双输卵管、卵     

二次肿瘤细胞减灭术在复发性上皮性卵巢癌治疗中的作用

为研究二次肿瘤细胞减灭术对复发性上皮性卵巢癌患者的作用,对首次治疗后、二次肿瘤细胞减灭术前无瘤生存时间>6个月的106例进行分析。 结果发现:106例复发的上皮性卵巢癌患者中87例(82.1％)在二次肿瘤细胞减灭术时清除了所有可见的病灶。在二次手术前应用挽救性化疗的患者中,64.3％能进行完全的肿瘤细胞减灭术,而93.8％的未应用挽救性化疗的患者能进行完全的肿瘤细胞减灭术;术前GOG评分为0、1、2和3分可进     

一线治疗无效的卵巢上皮癌患者第二次细胞减灭术

卵巢上皮癌的细胞减灭术是一公认的重要治疗措施,许多作者提出在首次手术后,残存灶极小的病人改善了生存率。作者报道1977年1月1日～1984年12月31日在 Anderson 肿瘤中心的115例患者进行第二次细胞减灭术。所有患者于第一次减灭术后均接受了化疗。其中33例在完成预定化疗前,因临床发现疾病稳定(2例)和疾病进展(31例)而进行第二次细胞减灭术。33例诊断时平均年龄54岁。按 FIGO 标准:Ⅰ+Ⅱ期18％,Ⅲ期67％,Ⅳ期9％,未分期6％。病理分级:Ⅰ级6％,Ⅱ级24％,Ⅲ级58％,未分级12％。组织学类型:浆液性42％,未分化癌12％,糖液性9％,内膜样癌9％,透明细胞癌9％,棍合性癌18％。手术力求彻底,主要范围是:切除肿瘤而不包     

复发性卵巢上皮癌再次手术预后因素系统评价

目的探讨复发性卵巢上皮癌再次肿瘤细胞减灭术的预后因素及病例选择标准。方法采用系统评价的方法,收集国内外2003年1月至2007年12月公开发表的二次手术治疗复发性卵巢癌的临床资料,进行分析。制定严格的纳入和排除标准。将可能影响再次肿瘤细胞减灭术中位生存期的预后因素进行定性评价。结果 12篇文献符合纳入标准。具有统计学意义的预后因素包括复发灶的多少、无疾病进展期(DFI)长短、初次手术残余灶大小、最大复发灶的直径,腹水的有无,再次手术残余灶大小。结论满足良好预后的因素为:(1)孤立的复发灶。(2)DFI≥12个月。(3)初次手术时达到理想的肿瘤细胞减灭术。(4)复发时腹水≤500mL。(5)进行了理想的再次肿瘤细胞减灭术。     

复发性卵巢上皮性癌再次手术的临床评价

目的　探讨复发性卵巢上皮性癌 (卵巢癌 )再次手术的指征及临床意义。方法　复发性卵巢癌再次手术的患者 5 5例 ,术前及术后均进行化学药物治疗 (化疗 )或放射治疗 (放疗 ) ,再次手术共 6 8例次。根据再次手术前不同病灶的性质分为 4组 ,即单个复发灶组、多个复发灶组、因肠梗阻手术组及姑息性手术组。并根据再次手术前对化疗的敏感程度分为 3组 ,即≤ 6个月复发组、>6个月复发组及肿瘤进展组。观察每组再次手术中进行满意的肿瘤细胞减灭术的例数、手术并发症的例数及手术治疗的有效率、生存时间、疾病缓解时间。结果　再次手术前通过检查认为是单个复发灶者 ,6 1%在再次手术中发现为多个复发灶 ;单个复发灶组中获得较满意的肿瘤细胞减灭术的为 6 7% ,术前认为是单个复发灶者而在再次手术中确诊为多个复发灶者中 ,获得较满意的肿瘤细胞减灭术的为6 4 % ;多个复发灶组获得满意的肿瘤细胞减灭术的为 4 3%。再次手术治疗的有效率 ,以单个复发灶组最高 ;手术后疾病缓解时间及生存时间 ,也以单个复发灶组最长 ;单个复发灶组手术并发症少于多个复发灶组。获得满意的肿瘤细胞减灭术 ,停止化疗 >6个月复发组为 73% ;≤ 6个月复发组为80 % ;肿瘤进展组为 5 0 %。结论　单个复发灶组、停止化疗 >6个月复发组再次手     

卵巢交界性上皮性肿瘤临床分析

目的分析卵巢交界性上皮性肿瘤的临床特点、治疗及预后情况,并探讨影响卵巢交界性肿瘤复发及预后的相关因素。方法回顾性分析1980年1月至2009年8月间在北京大学人民医院诊断的卵巢交界性上皮性肿瘤130例,所有患者均经手术治疗及术后病理证实。且经正规肿瘤术后随访12～240个月。结果平均发病年龄为42.3岁;Ⅰ、Ⅱ、Ⅲ期分别为106、6、18例;浆液性、黏液性和其他病理类型各48、63、19例;49.0%(51/104)的患者CA125升高;1%有微乳头浸润,0.05%有浸润性种植;所有患者均进行手术治疗,其中42.3%保留生育功能。复发率为6%(8例),其中18例行卵巢肿物剥除术2例复发,34例单侧或双侧附件切除术未见复发。肿瘤分期手术与一侧附件切除及单纯肿物剥除术的5年及10年存活率分别为100%、100%、95%。结论卵巢交界性肿瘤发病年龄较轻,Ⅰ期为主,黏液性肿瘤多见,预后良好,手术是主要的治疗手段,对早期患者行保留生育功能的手术是安全有效的,术后需长期随访。FIGO分期、微乳头型病变,浸润性种植及初次术后是否残留是影响复发及预后的相关因素。     

Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases

OBJECTIVES: The aim of this study was to determine the value of optimal cytoreduction in stage IV epithelial ovarian cancer. METHODS: A retrospective review was performed of 37 women with stage IV epithelial ovarian cancer treated by radical surgery. RESULTS: Optimal surgery to less than 2 cm tumor deposits was performed in 16 of the 37 cases (43%) and tumor debulking to less than 1 cm tumor deposits in 6 cases (16.2%). Twenty-three cases (62%) were designated stage IV because of the presence of liver metastases alone. Although no patients died within 2 weeks of surgery, 7 of the 37 cases (22%) failed to survive more than 50 days after primary surgery. The overall median survival was 11 months with overall 2- and 5-year survivals of 23 and 9%, respectively. On multivariate analysis comparing age, histological type, tumor grade, place of surgery, secondary surgical procedure, performance of bowel surgery, presence of liver metastases, and optimal cytoreduction, only optimal surgery and residual tumor deposits of less than 2 cm, or less than 1 cm, remained highly significant (P = 0.0029 and 0.0086, respectively). Even when assessing only the 27 cases who were designated as having stage IV disease because of the presence of liver metastases, by multivariate analysis, only optimal surgery and residual tumor deposits of less than 2 cm, or less than 1 cm, remained significant (P = 0.023 and 0.036, respectively). Site of metastases designating stage IV status was not associated with a reduced likelihood of achieving optimal debulking (P = 0.18). CONCLUSION: Optimal cytoreduction in women with stage IV epithelial ovarian cancer with or without hepatic metastases is associated with a more favorable outcome survival.     

18例妇科恶性肿瘤结肠、直肠手术临床分析

目的 探讨结肠、直肠手术在治疗卵巢上皮性癌和原发腹膜癌患者的手术指征和治疗效果。方法 对1988年6月～2001年5月在我院妇科接受开腹手术同时行结肠、直肠手术的18例妇科恶性肿瘤进行回顾性分析,其中卵巢上皮性癌16例,原发腹膜癌2例。结果 8例(44.4％)在初次手术中完成结肠、直肠手术,10例(55.6％)在处理复发性癌或者姑息性手术中进行。18例中接受结肠切除或者部分乙状结肠直肠手术,肠吻合术14例,其中3例手法吻合和11例吻合器吻合;4例接受结肠造瘘术患者中,1例于造瘘术后14个月行结肠造瘘还纳术。手术并发症为发热6例,腹泻3例,伤口延期愈合2例以及1例于术后49d因肿瘤进展和突发急性心肌梗塞死亡。17/18例切除肠管者术后病理示肿瘤侵犯至肠浆膜层7例,至浆肌层5例,至粘膜下层3例,至粘膜层2例。7例术后残留癌<2cm,10例>2cm,1例行姑息性手术未切除肠管。术后1年生存率为76％,2年为29％,3年为19％。2例术后存活已超过5年。结论 对卵巢上皮性癌或原发性腹膜癌患者实施结肠、直肠手术是为达到肿瘤细胞减灭或者为缓解肠梗阻症状。对可疑卵巢恶性肿瘤患者术前宜作肠道准备,术中尽量选择肠切除、肠吻合,减少结肠造瘘。对于某些妇科恶性肿瘤患者为提高治疗效果行部分肠管切除是值得的。     

Metastatic ovarian tumors: a review of 64 cases

OBJECTIVE: The goal was to review cases of metastatic ovarian tumor with respect to their clinical features. METHODS: Sixty-four patients with pathologically confirmed metastatic ovarian carcinoma, who were treated between 1978 and 2002 at Osaka Medical Center for Cancer and Cardiovascular Diseases (OMCC), were reviewed and the clinical features examined. RESULTS: We found that metastatic tumors accounted for 21.1% (64/304) of malignant ovarian tumors. Of 64 metastatic ovarian tumors, 26 originated from gynecologic organs, and 38, from nongynecologic organs. Gynecologic primary sites were the uterine body (23%), uterine cervix (14%), and fallopian tube (3%). Eight of nine cervical cancers with ovarian metastases were adenocarcinomas. Adenocarcinoma of the uterine cervix metastasized to the ovaries more frequently than squamous cell carcinoma (5.6% vs 0.1%, respectively; P < 0.01). Among 38 cases of metastatic ovarian tumors from nongynecologic organs, Krukenberg tumors, pathologically characterized by the presence of typical signet-ring cells, were found in 11 patients (29%). Most (8/11) had originated in the stomach. Half (19/38) were preoperatively diagnosed as metastases. The 5-year survival rate after resection of metastatic ovarian tumors from gynecologic organs was significantly higher than the rate after resection of such tumors from nongynecologic organs (47% vs 19%, respectively; P = 0.026). CONCLUSIONS: Metastatic ovarian tumors are likely to be relatively common in Japan because of the high incidence of gastric cancer. In cases of pelvic tumor, metastatic ovarian tumor should always be included in the differential diagnoses. As the 5-year survival after resection of metastatic ovarian tumor is 19%, even for tumors from nongynecologic organs, it seems worthwhile to consider tumorectomy as the second cytoreduction.     

The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns

OBJECTIVES: The aim of this study was to assess the safety, efficacy and impact on survival of low anterior resection and primary anastomosis at the time of en bloc resection for primary and recurrent epithelial ovarian carcinoma. METHODS: We performed a retrospective review of 46 primary and 14 recurrent epithelial ovarian carcinoma patients who underwent procedures between April 2001 and May 2005 in our center. Data were obtained from patient medical records and the cancer registry. Parameters for safety, efficacy and survival were considered as primary endpoints. RESULTS: For primary advanced ovarian cancer patients, 43.5% showed no visible tumor at the completion of surgery and optimal cytorection (residual tumor [RT] less than or equal 5 mm) was achieved in 89.2%. Complications associated with en bloc resection occurred in two patients (1 leakage of anastomosis site and 1 rectovaginal fistula), and these were managed with diversion colostomy. Patients with no visible residual tumor had longer disease-free survival compared to those with visible RT (median, 30 vs. 7 months; P=0.0082) and longer overall survival (3-year survival rate, 82.03% vs. 66.63%; P=0.0437). Patients with rectal invasions up to the serosa/subserosa had longer disease-free survival than those with rectal invasion up to the muscle/mucosa (P=0.0176) but did not differ significantly in terms of overall survival (P=0.0880). For recurrent ovarian cancer patients, 42.9% showed no visible tumor at the completion of surgery and optimal cytorection was achieved in 64.3%. One patient experienced an en-bloc-resection-associated complication (a rectovaginal fistula), which was managed conservatively. Patients with no visible residual tumor (RT) had longer disease-free survival than visible RT patients (median, not reached vs. 5 months; P=0.0156) but did not differ significantly in terms of overall survival (median, 32 months for no visible RT vs. 24 months for visible RT patients; P=0.0833). There were no surgery-related deaths among the overall 60 primary and recurrent ovarian cancer patients. CONCLUSIONS: En bloc resection of primary and recurrent epithelial ovarian carcinomas with low anterior resection permits a high rate of complete debulking with acceptable morbidity and mortality rates. Patients with no visible RT after surgery had a survival advantage over patients with visible RT.     

卵巢恶性肿瘤保留生育功能治疗52例临床分析

目的:评价卵巢恶性肿瘤保留生育功能手术和化疗对生育和卵巢功能的影响.方法:回顾性分析我院1996年6月至2010年6月卵巢恶性肿瘤行保留生育功能治疗并有完整随访资料的52例患者的临床资料,对其手术、术后化疗及术后月经和妊娠情况进行分析,并对是否行全面分期手术和不同病理类型行保留生育功能治疗后的生存率和复发率相比较,以及是否化疗的妊娠率进行比较.结果:52例患者中生殖细胞恶性肿瘤25例,上皮性恶性肿瘤12例,交界性肿瘤15例.复发3例,其中1例死亡.计划妊娠41例中妊娠成功16例,2例流产.术后化疗的38例患者中,2例化疗期间月经正常,36例在化疗1～2次后停经,但停止化疗后月经恢复.52例患者中行全面分期手术(15例)的生存率和复发率与行附件切除术或卵巢肿瘤剥除术(37例)比较,差异均无统计学意义(P均＞0.05).3种病理类型肿瘤患者保留生育功能治疗后的生存率和死亡率比较,差异均无统计学意义(P＞0.05).化疗患者中的妊娠率与未化疗患者的妊娠率比较,差异也无统计学意义(X2 =0.1186,P＞0.05).结论:卵巢恶性肿瘤保留生育功能治疗是有效和可行的,化疗对卵巢功能可能有影响,但可以逆转.保留生育功能手术以附件切除术或病灶切除术为宜,但结论尚有待大样本量研究及长期随访.     

165例卵巢恶性肿瘤不全分期术后行再分期手术必要性的临床初探#br#

Objective?To investigate the necessity of the re-staging operation after incomplete staging of epithelial cancer, ovarian malignant germ cell tumor and sex cord stromal tumor. Methods?A retrospective analysis was made on 165 ovarian cancer patients with surgical stageⅠA~ⅠC after incomplete staging operation who underwent re-staging operation in the First Affiliated Hospital of Zhengzhou University from January 2013 to January 2021. There were 85 cases in the epithelial carcinoma group, 31 cases in the malignant germ cell tumor group and 49 cases in the malignant sex cord stromal tumor group. Results?The rate of benefit from re-staging operation (surgical-pathological staging upgraded after re-staging operation) was 36.47% (31/85) in the epithelial cancer group, which was significantly higher than that in the germ cell tumor group (9.68%, 3/31) and sex cord stromal tumor group (4.08%, 2/49), the difference was statistically significant (P<0.05). The rates of benefit from re-staging operation among epithelial cancer, germ cell tumor and sex cord stromal tumor patients who had no residual impression tumor in incomplete staging operation are 33.33%(27/81), 3.44%(1/29) and 0%(0/47), which are significantly lower than that in the patients who had residual impression tumor in incomplete staging operation (P<0.05); The rates of benefit from re-staging operation among epithelial cancer, germ cell tumor and sex cord stromal tumor patients who had no positive imaging findings before re-staging are 34.15%(28/82), 3.44%(1/29) and 2.08%(1/48), which are significantly lower than that in the patients who had positive imaging findings before re-staging (P<0.05). Conclusion?The epithelial ovarian carcinoma with early surgical stage in incomplete staging operation should be treated with re-staging surgery after incomplete staging surgery; When there are residual tumor in incomplete staging operation or positive imaging findings before re-staging in the early surgical stage germ cell tumors and in the early surgical stage sex cord stromal tumors, it is necessary to perform re-staging surgery for them.     

Long-term disease-free survival in three ovarian cancer patients with a single relapse

Recurrent ovarian cancer with long-term survival is uncommon and often associated with poor prognosis. We report three cases of patients with advanced ovarian cancer who have achieved long-term disease-free survival following a single prior relapse. Case 1 relapsed with a localized bulky tumor and received a complete surgical resection and chemotherapy. Case 2 had a persistent central pelvic tumor after debulking surgery and second-line chemotherapy, and yet achieved excellent control with concurrent chemoradiation to the true pelvis. Case 3 relapsed with paraaortic lymph node metastasis and probable lung metastasis (subsequently negated by positron emission tomography) and received chemotherapy alone. These three patients have since remained disease-free for 13, 12, and seven years, respectively, since their first relapse. We conclude that select patients can obtain long-term disease-free survival after the first relapse by accurate restaging and aggressive multimodality treatment.     

Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies

OBJECTIVE: To assess the value of P-glycoprotein (Pgp) expression in advanced epithelial ovarian cancer with regard to clinicopathological findings and disease prognosis. METHODS: Twenty-four cases diagnosed as primary epithelial ovarian malignancies, between 1993-1999, were enrolled in this study. All of the cases had undergone cytoreductive surgery and an optimal staging procedure. Following cytoreductive surgery, in 18 patients, cisplatin+cyclophosphamide, and in six patients, cisplatin+paclitaxel combination chemotherapy regimens were initiated. After six courses of chemotherapy, cases were evaluated by pelvic examination, transvaginal ultrasound, pelvi-abdominal tomography and serum Ca-125 levels for the presence of residual disease. Following this evaluation residual tumor was detected in 14 cases and secondary cytoreductive surgery was undergone. In ten cases without any clinical and laboratory confirmation of the presence of tumor, second-look laparotomy was performed. In 24 epithelial ovarian cancer cases, both in primary or secondary cytoreductive surgery, Pgp expression was determined by immunohistochemical methods. RESULTS: Following primary surgery, in 25% (6/24) of cases, analysis of tumor specimens showed presence of Pgp expression. In cases recurring after first-line chemotherapy, Pgp expression was not statistically different in regard to chemotherapy regimen (p = 0.098). Pgp expression in tumoral tissues after chemotherapy did show a higher Pgp expression than before chemotherapy (p = 0.016). No significant correlation was relevant between Pgp expression and Ca-125 levels, histopathological differentiation, histologic subgroups of tumor, primary and residual tumor sizes and overall survival. CONCLUSION: In epithelial ovarian cancer, Pgp expression has no effect on overall disease survival.